361 related articles for article (PubMed ID: 19401344)
21. Carboplatin dosing in children: calculation by different formulae.
Würthwein G; Krefeld B; Gerss J; Boos J
Onkologie; 2011; 34(1-2):16-22. PubMed ID: 21346380
[TBL] [Abstract][Full Text] [Related]
22. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level.
Ando M; Minami H; Ando Y; Saka H; Sakai S; Yamamoto M; Sasaki Y; Shimokata K; Hasegawa Y
Clin Cancer Res; 2000 Dec; 6(12):4733-8. PubMed ID: 11156227
[TBL] [Abstract][Full Text] [Related]
23. A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function.
Viberg A; Lannergård A; Larsson A; Cars O; Karlsson MO; Sandström M
Br J Clin Pharmacol; 2006 Sep; 62(3):297-303. PubMed ID: 16934045
[TBL] [Abstract][Full Text] [Related]
24. Novel algorithm for more accurate calculation of renal function in adults with cancer.
Holweger K; Lipp HP; Dietz K; Hartmann JT; Bokemeyer C
Ann Pharmacother; 2008 Dec; 42(12):1749-57. PubMed ID: 19033483
[TBL] [Abstract][Full Text] [Related]
25. Dose-banding of carboplatin: rationale and proposed banding scheme.
Kaestner S; Sewell G
J Oncol Pharm Pract; 2007 Jun; 13(2):109-17. PubMed ID: 17873111
[TBL] [Abstract][Full Text] [Related]
26. Estimation of glomerular filtration rate in cancer patients.
Wright JG; Boddy AV; Highley M; Fenwick J; McGill A; Calvert AH
Br J Cancer; 2001 Feb; 84(4):452-9. PubMed ID: 11207037
[TBL] [Abstract][Full Text] [Related]
27. Serum cystatin C is a suitable marker for routine monitoring of renal function in pediatric cancer patients, especially of very young age.
Lankisch P; Wessalowski R; Maisonneuve P; Haghgu M; Hermsen D; Kramm CM
Pediatr Blood Cancer; 2006 Jun; 46(7):767-72. PubMed ID: 16550534
[TBL] [Abstract][Full Text] [Related]
28. [Interest of cystatin C for individual dosing of anticancer drugs cleared by the kidneys].
Thomas F; Séronie-Vivien S; Malard L; Chatelut E
Therapie; 2007; 62(2):121-7. PubMed ID: 17582313
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of two dose individualisation methods for carboplatin.
Desoize B; Dufour R; Urien S; Kaltenbach M; Colin P
Anticancer Res; 1996; 16(4A):2073-8. PubMed ID: 8712745
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy.
Veal GJ; English MW; Grundy RG; Shakespeare C; Glaser A; Waters F; Holden V; O'Meara A; Michalski A; Howe K; Cole S; Boddy AV
Cancer Chemother Pharmacol; 2004 Oct; 54(4):295-300. PubMed ID: 15133627
[TBL] [Abstract][Full Text] [Related]
31. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
Huitema AD; Mathôt RA; Tibben MM; Schellens JH; Rodenhuis S; Beijnen JH
Clin Pharmacol Ther; 2000 Jun; 67(6):621-30. PubMed ID: 10872644
[TBL] [Abstract][Full Text] [Related]
32. [Usefulness of the formula for predicting creatinine clearance from serum cystatin C].
Oyabu C; Hayashi N; Sugiyama D; Umezu M; Kinoshita S; Hayashi H; Kawano S; Kumagai S
Rinsho Byori; 2008 Dec; 56(12):1093-9. PubMed ID: 19175073
[TBL] [Abstract][Full Text] [Related]
33. [Dose individualization for carboplatin in cancer chemotherapy].
Oudard S; Lauraine EP
Bull Cancer; 1997 Jun; 84(6):675-7. PubMed ID: 9295872
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2.
Schwartz J; Toste B; Dizon DS
Gynecol Oncol; 2009 Jul; 114(1):53-6. PubMed ID: 19359030
[TBL] [Abstract][Full Text] [Related]
35. How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients.
Bénézet S; Guimbaud R; Chatelut E; Chevreau C; Bugat R; Canal P
Ann Oncol; 1997 Jun; 8(6):607-9. PubMed ID: 9261532
[TBL] [Abstract][Full Text] [Related]
36. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation.
Winter MA; Guhr KN; Berg GM
Pharmacotherapy; 2012 Jul; 32(7):604-12. PubMed ID: 22576791
[TBL] [Abstract][Full Text] [Related]
37. Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors.
Kaag D
Lung Cancer; 2013 Jan; 79(1):54-8. PubMed ID: 23131495
[TBL] [Abstract][Full Text] [Related]
38. Variables affecting creatinine clearance prediction.
Sawyer WT; Canaday BR; Poe TE; Webb CE; Gal P; Joyner PU; Berry JI
Am J Hosp Pharm; 1983 Dec; 40(12):2175-80. PubMed ID: 6660232
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacokinetics and individual dose adjustment of carboplatin].
Chatelut E; Canal P; Bugat R
Bull Cancer; 2000 Aug; 87 Spec No():17-23. PubMed ID: 11082718
[TBL] [Abstract][Full Text] [Related]
40. Serum cystatin C: a surrogate marker for the characteristics of peritoneal membrane in dialysis patients.
Al-Wakeel JS; Hammad D; Memon NA; Tarif N; Shah I; Chaudhary A
Saudi J Kidney Dis Transpl; 2009 Mar; 20(2):227-31. PubMed ID: 19237809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
